Featured in NEJM Journal Watch: Dupilumab for Atopic Dermatitis; Secukinumab for Plaque Psoriasis — Physician’s First Watch
Featured in NEJM Journal Watch: Dupilumab for Atopic Dermatitis; Secukinumab for Plaque Psoriasis
By the NEJM Journal Watch Editors
This week, NEJM Journal Watch Dermatology summarizes two reports from the New England Journal of Medicine on treatment with fully human monoclonal antibodies.
In the first, investigators conducted four multicenter, randomized, double-blind, placebo-controlled clinical trials to evaluate treatment of moderate-to-severe atopic dermatitis with dupilumab, which inhibits both interleukin (IL)-4 and IL-13. Patients in the treatment group saw significant improvements in eczema severity and pruritus.
In the second, two studies of patients with plaque psoriasis found that injectable secukinumab, which selectively binds and neutralizes IL-17A, was more efficacious than etanercept or placebo for all endpoints.